Johnson & Johnson to launch on TrumpRx with 4 of its prescription drugs
Summary:
Johnson & Johnson becomes the latest pharmaceutical company to sign on to TrumpRx, now listing four of its most popular drugs for sale through the website, which redirects users to marketplaces run by the drug companies themselves.
FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug
Summary:
U.S. Food and Drug Administration is announcing that it issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol (EAP) for its experimental pancreatic cancer drug, daraxonrasib.
Verastem launches ‘Reimagine’ campaign to move ovarian cancer drugs into earlier lines
Summary:
Verastem’s “Reimagine” campaign encourages physicians and patients to use its newly approved Avmapki Fakzynja Co-Pack during the first recurrence of low-grade serous ovarian cancer. The digital initiative aims to move the therapy into earlier treatment lines to maximize long-term patient outcomes.
FDA hands Pfizer, Arvinas’ Veppanu early approval for breast cancer subtype
Summary:
The FDA granted early approval to Veppanu, the first-ever PROTAC therapy, for ESR1-mutated metastatic breast cancer. While validating Arvinas’ protein-degradation platform, the partners are out-licensing commercialization rights following mixed Phase 3 data that restricted the drug’s use to a specific patient subset.
Swiss BioTech startup ALP Bio raises €1.9 million to advance immune organoid and AI platform
Summary:
ALP Bio raised €1.9 million to accelerate its platform combining human immune organoids with generative AI. The technology predicts and reduces immunogenicity risks early in antibody development, helping pharmaceutical partners avoid costly late-stage clinical failures through more predictable, data-rich biological feedback.
